Open Access

Perivascular epitheloid cell tumor (PEComa) mimicking retroperitoneal liposarcoma

  • Moritz Wildgruber1Email author,
  • Karen Becker2,
  • Marcus Feith3 and
  • Jochen Gaa1
World Journal of Surgical Oncology201412:3

https://doi.org/10.1186/1477-7819-12-3

Received: 20 September 2013

Accepted: 27 December 2013

Published: 6 January 2014

Abstract

PEComas are a collection of generally rare tumors, defined by the World Health Organization as ‘mesenchymal tumors composed of histologically and immunohistochemically distinctive perivascular epitheloid cells’. We describe the case of retroperitoneal PEComa with a liposarcoma-like appearance on cross-sectional imaging, but distinctive immunohistochemistry revealing the correct diagnosis.

Keywords

PEComa Mesenchymal tumor Liposarcoma mTOR signaling

Background

Perivascular Epitheloid Cell tumors (PEComas) are rare mesenchymal tumors that can appear at various sites in the body and can be associated with the tuberous sclerosis complex. They can possess a heterogeneous appearance, ranging from poorly differentiated soft-tissue tumors to sclerosing masses. Lipid-rich PEComas are uncommon. We present the case of a large lipid-rich PEComa primarily misdiagnosed as a liposarcoma on computed tomography and magnetic resonance imaging. Histology, however, revealed a lipid-rich PEComa without any signs of malignancy, which required no further treatment following surgical resection.

Case presentation

A 75-year-old man was referred for abdominal computed tomography (CT) due to a poorly defined liver mass, detected by the primary care physician on ultrasound screening, which turned out to be a hemangioma. As an accidental finding, the contrast-enhanced CT scan additionally showed an 8 × 11 × 15 cm large retroperitoneal mass in the lower left abdomen adjacent to the sigmoid colon and the left psoas muscle (Figure 1A). The density measurements revealed that the thinly encapsulated mass consisted predominantly of fat with a few solid nodular structures. Contrast-enhanced magnetic resonance imaging (MRI) confirmed the lesion to be composed predominantly of fat with a few solid hypervascularized nodules (Figure 1B and C). The mass was palpable through the abdominal wall but painless. Laboratory findings indicated a mild anemia (hemoglobin 12.9 g/dl) but were otherwise unremarkable. The patient had no history of malignant or infectious disease.
Figure 1

Computed tomography (A) and magnetic resonance imaging findings (B and C) demonstrate an ovoid encapsulated retroperitoneal mass, which contained predominantly fat and a few solid hypervascularized nodules (arrows).

Due to the imaging findings, a retroperitoneal liposarcoma was suspected and the patient underwent surgery with resection of the mass and the adjacent sigmoid colon. Intraoperatively, the tumor showed firm adhesions both with the mesentery of the sigmoid colon as well as with the adjacent small bowel mesentery. During adhesiolysis, several tumor feeding vessel originating from the inferior mesenteric artery were identified and clamped. Due to the close proximity of the tumor to the sigmoid colon, the latter was resected en bloc together with the mass and a side-to-side descendo-rectostomy was performed. Macroscopic appearance as well as histology and immunohistochemistry of the mass are shown in Figure 2.
Figure 2

Macroscopic appearance (A) and histology with H&E staining (B) and immunohistochemistry (IHC) for smooth muscle actin (C) and human melanoma black (HMB)-45 (D).

Macroscopic evaluation of the surgical specimen confirmed the predominance of fat within the thinly encapsulated tumor (Figure 2A). Histology demonstrated the presence of large-sized lipid vacuoles and small, disseminated islands of lipoblasts (Figure 2B). Variable-sized nests of epitheloid cells were spread over the tumor. Immunohistochemically, these cells showed only weak staining for melan-A, desmin and smooth muscle actin (SMA) (Figure 2C). S-100 staining was negative but strong reaction was found for human melanoma black HMB-45 (Figure 2D). MiB1 staining revealed a proliferation rate < 1% and no mitoses were observed. A fluorescence in situ hybridization (FISH) for MDM2 gene amplification was negative, thus a liposarcoma was ruled out and the final diagnosis was lipid-rich perivascular epitheloid cell tumor (PEComa) without any signs of malignancy. The patient recovered well from surgery and did not require any further adjuvant treatment.

Discussion

PEComas are a rare mesenchymal tumor entity incorporating angiomyolipomas, clear ‘sugar’ cell tumors, lymphangioleiomyomas and histologically and immunophenotypically similar tumors occurring at various soft-tissue and visceral sites, and can be associated with the tuberous sclerosis complex [1, 2]. Distinctive epitheloid tumor cells show a focal association with blood vessels and express melanocytic and smooth muscle markers, the most sensitive being HMB-45 [3, 4].

PEComas have been described at various extrarenal locations including the mesentery, urinary bladder, liver, pancreas, rectum, heart and lung as well as in the bone [511]. Retroperitoneal localization of PEComas has been described [12, 13], but a liposarcoma-like aspect of the tumor in this localization as in our case is extremely rare. PEComas occurring in these non-classical locations have been termed ‘perivascular epitheloid cell tumors not otherwise specified’ (PEComa-NOS) [14, 15].

The imaging signature of PEComas is highly variable, although a few common features have been described. Mostly, PEComas have well defined borders and are of regular shape. The enhancement on cross-sectional imaging after contrast agent administration is usually inhomogeneous due to the heterogeneous composition of the tumor [16].

The degree of malignancy is highly variable in PEComas, but as with other sarcomas, the size of the primary tumor as well as the mitotic rate seem to be the most reliable prognostic factors associated with recurrence after surgical resection. Bleeker et al. have recently established a suggestion for risk stratification and treatment strategies [14]. If possible, surgical resection is the treatment of choice for PEComas and, as activation of the mTOR signaling pathway is common in these tumors, mTOR inhibitors such as rapamycin have been successfully applied as medical treatment . Although no large series of patients treated with mTOR inhibitors exist, preliminary data suggest that complete response is possible [17].

With a size > 5 cm but absent further risk factors such as infiltrative growth pattern, high nuclear grade and cellularity, mitotic rate > 1/50 HPF, necrosis or vascular invasion, the tumor in our patient was stratified as ‘uncertain malignant potential’ according to the modified Folpe criteria [14]. According to these criteria, adjuvant therapy may be of benefit in patients with high risk of recurrence, which was not considered to be present in our patient. However, regardless of the postoperative strategy employed, long-term surveillance should be at its core, as recurrences have been reported more than five years following resection [14]. Our patient is scheduled for clinical follow-up evaluation every six months for the first five years and, similar to sarcoma patients, with contrast-enhanced MRI every six months in the first three years and subsequent annual MRI examinations thereafter. Today, one and a half years after surgical resection, the patient is free of recurrence.

Conclusion

Although a rare tumor entity, PEComas are occasionally found as usually well-circumscribed tumors, often located in the abdomen, retroperitoneum or the pelvis. Besides surgical resection as the treatment option of choice, clinicians should be aware of new treatment strategies using inhibitors of the mTOR signaling pathway, which is commonly activated in PEComas.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations

CT: 

Computed tomography

HPF: 

High-power field

MRI: 

Magnetic resonance imaging

mTOR: 

Mamallian target of rapamycin

PEComa: 

Perivascular epitheloid cell tumor.

Declarations

Authors’ Affiliations

(1)
Department of Diagnostic and Interventional Radiology, Klinikum Rechts der Isar, TU München
(2)
Department of Pathology, Klinikum Rechts der Isar, Technische Universität München
(3)
Department of Surgery, Klinikum Rechts der Isar, Technische Universität München

References

  1. Bonetti F, Pea M, Martignoni G, Doglioni C, Zamboni G, Capelli P, Rimondi P, Andrion A: Clear cell (‘sugar’) tumor of the lung is a lesion strictly related to angiomyolipoma -the concept of a family of lesions characterized by the presence of the perivascular epithelioid cells (PEC). Pathology. 1994, 26: 230-236. 10.1080/00313029400169561.View ArticlePubMedGoogle Scholar
  2. Zamboni G, Pea M, Martignoni G, Zancanaro C, Faccioli G, Gilioli E, Pederzoli P, Bonetti F: Clear cell ‘sugar’ tumor of the pancreas. A novel member of the family of lesions characterized by the presence of perivascular epithelioid cells. Am J Surg Pathol. 1996, 20: 722-730. 10.1097/00000478-199606000-00010.View ArticlePubMedGoogle Scholar
  3. Folpe AL, Mentzel T, Lehr HA, Fisher C, Balzer BL, Weiss SW: Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol. 2005, 29: 1558-1575. 10.1097/01.pas.0000173232.22117.37.View ArticlePubMedGoogle Scholar
  4. Pan CC, Jong YJ, Chai CY, Huang SH, Chen YJ: Comparative genomic hybridization study of perivascular epithelioid cell tumor: molecular genetic evidence of perivascular epithelioid cell tumor as a distinctive neoplasm. Hum Pathol. 2006, 37: 606-612. 10.1016/j.humpath.2006.01.008.View ArticlePubMedGoogle Scholar
  5. Desy NM, Bernstein M, Nahal A, Aziz M, Kenan S, Turcotte RE, Kahn LB: Primary perivascular epithelioid cell neoplasm (PEComa) of bone: report of two cases and review of the literature. Skeletal Radiol. 2012, 41: 1469-1474. 10.1007/s00256-012-1479-1.View ArticlePubMedGoogle Scholar
  6. Fu X, Jiang JH, Gu X, Li Z: Malignant perivascular epithelioid cell tumor of mesentery with lymph node involvement: a case report and review of literature. Diagn Pathol. 2013, 8: 60-10.1186/1746-1596-8-60.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Im S, Yoo C, Jung JH, Choi HJ, Yoo J, Kang CS: Primary perivascular epithelioid cell tumor in the rectum: a case report and review of the literature. Indian J Pathol Res Pract. 2013, 209: 244-248. 10.1016/j.prp.2013.01.001.View ArticleGoogle Scholar
  8. Mourra N, Lazure T, Colas C, Arrive L, de Gramont A: Perivascular epithelioid cell tumor: the first malignant case report in the pancreas. Appl Immunohistochem Mol Morphol. 2013, 21: e1-e4.View ArticlePubMedGoogle Scholar
  9. Neri S, Ishii G, Aokage K, Hishida T, Yoshida J, Nishimura M, Nagai K: Multiple perivascular epithelioid cell tumors: clear cell tumor of the lung accompanied by angiomyolipoma of the liver. Ann Thorac Cardiovasc Surg. 2013Google Scholar
  10. Yin L, Bu H, Chen M, Yu J, Zhuang H, Chen J, Zhang H: Perivascular epithelioid cell neoplasm of the urinary bladder in an adolescent: a case report and review of the literature. Diagn Pathol. 2012, 7: 183-10.1186/1746-1596-7-183.PubMed CentralView ArticlePubMedGoogle Scholar
  11. Zhao LJ, Yang YJ, Wu H, Huang SM, Liu K: Perivascular epithelioid cell tumor of the liver: a case report and literature review. Eur Rev Med Pharmacol Sci. 2013, 17: 1665-1668.PubMedGoogle Scholar
  12. Hornick JL, Fletcher CD: Sclerosing PEComa: clinicopathologic analysis of a distinctive variant with a predilection for the retroperitoneum. Am J Surg Pathol. 2008, 32: 493-501. 10.1097/PAS.0b013e318161dc34.View ArticlePubMedGoogle Scholar
  13. Shin JS, Spillane A, Wills E, Cooper WA: PEComa of the retroperitoneum. Pathology. 2008, 40: 93-95. 10.1080/00313020701716300.View ArticlePubMedGoogle Scholar
  14. Bleeker JS, Quevedo JF, Folpe AL: ‘Malignant’ perivascular epithelioid cell neoplasm: risk stratification and treatment strategies. Sarcoma. 2012, 2012: 541626-PubMed CentralView ArticlePubMedGoogle Scholar
  15. Fadare O, Parkash V, Yilmaz Y, Mariappan MR, Ma L, Hileeto D, Qumsiyeh MB, Hui P: Perivascular epithelioid cell tumor (PEComa) of the uterine cervix associated with intraabdominal ‘PEComatosis’: a clinicopathological study with comparative genomic hybridization analysis. World J Surg Oncol. 2004, 2: 35-10.1186/1477-7819-2-35.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Tan Y, Zhang H, Xiao EH: Perivascular epithelioid cell tumor: dynamic CT, MRI and clinicopathological characteristics - analysis of 32 cases and review of the literature. Clin Radiol. 2013, 68: 555-561. 10.1016/j.crad.2012.10.021.View ArticlePubMedGoogle Scholar
  17. Dickson MA, Schwartz GK, Antonescu CR, Kwiatkowski DJ, Malinowska IA: Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates. Int J Cancer. 2013, 132: 1711-1717. 10.1002/ijc.27800.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Wildgruber et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement